Our RESETTM clinical trials with rese-cel (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, and pemphigus vulgaris are now recruiting.
Latest Financial Results
Q2 2026
Quarter Ended Jun 30, 2026
Latest 10-K
Financials
View the latest financials